Endothelin-mediated oncofetal fibronectin expression in chronic allograft nephropathy

Transplantation

Volumn 82, Issue 3, 2006, Pages 406-414

  Siddiqui, Iram ^a   Khan, Zia A ^a,b   Lian, Dameng ^a   Jiang, Jifu ^a   Zhong, Robert ^a   Garcia, Bertha ^a   Chakrabarti, Subrata ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Chronic rejection; Endothelins; Fibronectin; Fibrosis

Indexed keywords

BOSENTAN; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; EXTRA DOMAIN B FIBRONECTIN; FIBRONECTIN; SCLEROPROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ADULT; AGED; ALTERNATIVE RNA SPLICING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC ALLOGRAFT NEPHROPATHY; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY BIOPSY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; ANIMALS; BIOPSY; CHILD; CHRONIC DISEASE; ENDOTHELIN-1; FEMALE; FIBRONECTINS; GENE EXPRESSION REGULATION; GRAFT REJECTION; HUMANS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; NEPHRITIS; PROTEIN ISOFORMS; RATS; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA; TRANSPLANTATION, HOMOLOGOUS;

EID: 33747144879     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000228905.44649.06     Document Type: Article

References (46)

1. Hayry P, Isoniemi H, Yilmaz S, et al. Chronic allograft rejection. Immun Rev 1993; 134: 33.
2. Hosenpud JD, Bennett LE, Keck BM, et al. The Registry of the International Society for Heart and Lung Transplantation: Seventeenth official report 2000. J Heart Lung Transplant 2000; 19: 909.
3. Hillebrands JL, Rozing J. Chronic transplant dysfunction and transplant arteriosclerosis: new insights into underlying mechanisms. Expert Rev Mol Med 2003: 1.
4. Tullius SG, Heemann U, Hancock WW, et al. Long-term kidney isografts develop functional and morphologic changes that mimic those of chronic allograft rejection. Ann Surg 1994; 220: 425.
5. Coito AJ, Kupiec-Weglinski JW. Extracellular matrix proteins: bystanders or active participants in the allograft rejection cascade? Ann Transplant 1996; 1: 14.
6. Deng DX, Jiang J, Garcia B, et al. Endothelin-1, endothelin-3 and their receptors (endothelin (A) and endothelin (B)) in chronic renal transplant rejection in rats. Transpl Int 2000; 13: 175.
7. Watschinger B, Sayegh MH, Hancock WW, Russell ME. Upregulation of endothelin-1 mRNA and peptide expression in rat cardiac allografts with rejection and arteriosclerosis. Am J Pathol 1995; 146: 1065.
8. El-Gamel A, Sim E, Hasleton P, et al. Transforming growth factor beta (TGF-beta) and obliterative bronchiolitis following pulmonary transplantation. J Heart Lung Transplant 1999; 18: 828.
9. Hayry P, Paavonen T, Mennander A, et al. Pathophysiology of allograft arteriosclerosis. Transplant Proc 1993; 25(2): 2070.
10. Orosz CG, Pelletier RP. Chronic remodeling pathology in grafts. Curr Opin Immunol 1997; 9: 676.
11. Gould VE, Martinez-Lacabe V, Virtanen I, et al. Differential distribution of tenascin and cellular fibronectins in acute and chronic renal allograft rejection. Lab Invest 1992; 67: 71.
12. Castellani P, Dorcaratto A, Pau A, et al. The angiogenesis marker ED-B+ fibronectin isoform in intracranial meningiomas. Acta Neurochir (Wien) 2000; 142: 277.
13. Nanki N, Fujita J, Yang Y, et al. Expression of oncofetal fibronectin and syndecan-1 mRNA in 18 human lung cancer cell lines. Tumour Biol 2001; 22: 390.
14. Sakai M, Sasaki Y, Yamagishi N, et al. The preterm labor index and fetal fibronectin for prediction of preterm delivery with intact membranes. Obstet Gynecol 2003; 101: 123.
15. Castellani P, Viale G, Dorcaratto A, et al. The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int J Cancer 1994; 59(5): 612.
16. Khan ZA, Cukiernik M, Gonder JR, Chakrabarti S. Oncofetal fibronectin in diabetic retinopathy. Invest Ophthalmol Vis Sci 2004; 45: 287.
17. Khan ZA, Barbin YP, Farhangkhoee H, et al. Glucose-induced serum and glucocorticoid-regulated kinase activation in oncofetal fibronectin expression. Biochem Biophys Res Commun 2005; 329: 275.
18. Khan ZA, Caurtero J, Barbin YP, et al. ED-B fibronectin in non-small cell lung carcinoma. Exp Lung Res 2005; 31: 701.
19. Khan ZA, Chan BM, Uniyal S, et al. EDB fibronectin and angiogenesis - a novel mechanistic pathway. Angiogenesis 2005; 8: 183.
20. Simonson MS, Herman WH, Robinson A, et al. Inhibition of endothelinconverting enzyme attenuates transplant vasculopathy and rejection in rat cardiac allografts. Transplantation 1999; 67: 1542.
21. Diamond JR, Tilney NL, Frye J, et al. Progressive albuminuria and glomerulosclerosis in a rat model of chronic renal allograft rejection. Transplantation 1992; 54: 710.
22. Chandraker A, Azuma H, Nadeau K, et al. Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection. J Clin Invest 1998; 101: 2309.
23. Clozel M, Breu V, Gray GA, et al. Pharmacological characterization of bosentan, a new potent orally active non-peptide endothelin receptor antagonist. J Pharmacol Exp Ther 1994; 270: 228.
24. Grant D, Zhong R, Stiller C, et al. A comparison of cyclosporine A and Nva2-cyclosporine (cyclosporine G) in a rat renal allograft model. Transplantation 1987; 44: 9.
25. Evans T, Deng DX, Chen S, Chakrabarti S. Endothelin receptor blockade prevents augmented extracellular matrix component mRNA expression and capillary basement membrane thickening in the retina of diabetic and galactose-fed rats. Diabetes 2000; 49: 662.
26. Deng D, Evans T, Mukherjee K, et al. Diabetes-induced vascular dysfunction in the retina: role of endothelins. Diabetologia 1999; 42: 1228.
27. Racusen LC. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
28. Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411.
29. Isoniemi H, Taskinen E, Hayry P. Histological chronic allograft damage index accurately predicts chronic renal allograft rejection. Transplantation 1994; 58: 1195.
30. Chen S, Mukherjee S, Chakraborty C, Chakrabarti S. High glucose induced, endothelin-dependent fibronectin synthesis is mediated via NF-kappa B and AP-1. Am J Physiol 2003; 284: C263.
31. Chen S, Evans T, Deng D, et al. Hyperhexosemia induced functional and structural changes in the kidneys: role of endothelins. Nephron 2002; 90: 86.
32. King AJ, Brenner BM, Anderson S. Endothelin: a potent renal and systemic vasoconstrictor peptide. Am J Physiol 1989; 256: F1051.
33. Watschinger B, Sayegh MH. Endothelin in organ transplantation. Am J Kidney Dis 1996; 27: 151.
34. Clozel M, Salloukh H. Role of endothelin in fibrosis and anti-fibrotic potential of bosentan. Ann Med 2005; 37: 2.
35. Muldoon LL, Rodland KD, Forsythe ML, Magun BE. Stimulation of phosphatidylinositol hydrolysis, diacylglycerol release and gene expression in response to endothelin, a potent new agonist for fibroblasts and smooth muscle cells. J Biol Chem 1989; 264: 8529.
36. Jarnagin WR, Rockey DC, Koteliansky VE, et al. Expression of variant fibronectins in wound healing: Cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis. J Cell Biol 1994; 127: 2037.
37. Chen S, Khan ZA, Cukiernik M, Chakrabarti S. Differential activation of NF-kappa B and AP-1 in increased fibronectin synthesis in target organs of diabetic complications. Am J Physiol Endocrinol Metab 2003; 284: E1089.
38. Clozel M. Effects of bosentan on cellular processes involved in pulmonary arterial hypertension: do they explain the long-term benefit? Ann Med 2003; 35: 605.
39. Zhang K, Rekhter MD, Gordon D, Phan SH. Myofibroblasts and their role in lung collagen gene expression during pulmonary fibrosis. A combined immunohistochemical and in situ hybridization study. Am J Pathol 1994; 145: 114.
40. Hayry P, Paavonen T, Mennander A, et al. Pathophysiology of allograft arteriosclerosis. Transplant Proc 1993; 25: 2070.
41. Orosz CG, Pelletier RP. Chronic remodeling pathology in grafts. Curr Opin Immunol 1997; 9(5): 676.
42. Barnes JL, Torres ES, Mitchell RJ, Peters JH. Expression of alternatively spliced fibronectin variants during remodeling in proliferative glomerulonephritis. Am J Pathol 1995; 147: 1361.
43. Coito AJ, Brown LF, Peters JH, et al. Expression of fibronectin splicing variants in organ transplantation: a differential pattern between rat cardiac allografts and isografts. Am J Pathol 1997; 150: 1757.
44. Baczkowska T. Serum TGF-beta1 correlates with chronic histopathological lesions in protocol biopsies of kidney allograft recipients. Transplant Proc 2005; 37: 773.
45. Matl I, Viklicky O. Transforming growth factor (TGF-beta) and kidney transplantation. Cas Lek Cesk 2002; 141: 601.
46. Baczkowska T. Serum TGF-beta1 correlates with chronic histopathological lesions in protocol biopsies of kidney allograft recipients. Transplant Proc 2005; 37(2): 773.